Corient Private Wealth LLC Buys 60 Shares of Humana Inc. (NYSE:HUM)

Corient Private Wealth LLC grew its holdings in shares of Humana Inc. (NYSE:HUM) by 0.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 27,460 shares of the insurance provider’s stock after buying an additional 60 shares during the quarter. Corient Private Wealth LLC’s holdings in Humana were worth $12,572,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. NBC Securities Inc. acquired a new position in shares of Humana in the 3rd quarter valued at $291,000. Wilbanks Smith & Thomas Asset Management LLC boosted its holdings in shares of Humana by 83.7% during the 3rd quarter. Wilbanks Smith & Thomas Asset Management LLC now owns 1,062 shares of the insurance provider’s stock worth $517,000 after purchasing an additional 484 shares during the last quarter. Nicholas Hoffman & Company LLC. purchased a new stake in shares of Humana during the 3rd quarter valued at approximately $212,000. HBK Sorce Advisory LLC purchased a new stake in shares of Humana during the 3rd quarter valued at approximately $208,000. Finally, Mawer Investment Management Ltd. raised its position in Humana by 10.3% in the third quarter. Mawer Investment Management Ltd. now owns 11,038 shares of the insurance provider’s stock valued at $5,370,000 after purchasing an additional 1,028 shares during the period. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 0.8 %

Shares of HUM stock traded down $2.92 during trading hours on Friday, reaching $349.30. 1,583,481 shares of the stock traded hands, compared to its average volume of 1,637,297. The business has a fifty day moving average price of $324.36 and a 200 day moving average price of $371.63. Humana Inc. has a 1-year low of $298.61 and a 1-year high of $530.54. The firm has a market capitalization of $42.09 billion, a PE ratio of 21.75, a PEG ratio of 2.05 and a beta of 0.50. The company has a quick ratio of 1.67, a current ratio of 1.67 and a debt-to-equity ratio of 0.77.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping analysts’ consensus estimates of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The business had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. During the same period in the previous year, the company earned $9.38 earnings per share. Humana’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, equities research analysts forecast that Humana Inc. will post 16.18 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.885 dividend. The ex-dividend date is Friday, June 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.01%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Wall Street Analyst Weigh In

HUM has been the subject of a number of analyst reports. StockNews.com downgraded shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 26th. Stephens decreased their price objective on shares of Humana from $550.00 to $430.00 and set an “overweight” rating for the company in a research note on Friday, January 26th. Bank of America upped their price objective on shares of Humana from $342.00 to $376.00 and gave the company a “neutral” rating in a research note on Monday, May 20th. Barclays decreased their target price on shares of Humana from $356.00 to $310.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 2nd. Finally, Royal Bank of Canada decreased their target price on shares of Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research note on Thursday, April 25th. Eleven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $426.39.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.